No Data
No Data
No Data
No Data
No Data
Lipocine Initiates New ATM Offering, Ends Previous Agreement
TipRanks05:33
Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial
Lipocine (LPCN) said Thursday that a phase 2 trial of LPCN 2401 showed improved body composition in participants with obesity. LPCN 2401 demonstrated increased lean mass by 4.4% and reduced fat mass b
MT NewswiresApr 13 01:35
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersEliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. The market value of their outstanding shares is at $112.2 million. Rallybio (NASDAQ:
BenzingaApr 11 20:10
Lipocine Reports Positive Results From Obesity Treatment Trial
InvestingApr 11 19:54
Top Premarket Gainers
Rallybio Corp. (RLYB) shares nearly doubled Thursday premarket after the company said it formed a collaboration with Johnson & Johnson to develop therapies for pregnant women at risk of fetal and neon
MT NewswiresApr 11 19:44
Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity
Lipocine Announced Results From A Phase 2 Trial Of LPCN 2401 Showing Significant Improvement In Body Composition Through Decreased Fat Mass And Increased Lean Mass Or Fat-free Mass In Obese Patients With At Least One Weight-related Comorbidity
BenzingaApr 11 19:04
No Data
No Data